Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1994-4-26
|
| pubmed:abstractText |
Nonarterialized orthotopic liver transplantation with no immunosuppression was performed in 13 mouse-strain combinations. Two strain combinations with major histocompatibility complex class I and class II and minor histocompatibility complex disparity had 20% and 33% survival of more than 100 days, but the other 11 combinations, including four that were fully allogeneic and all with only class I, class II or minor disparities, yielded 45% to 100% survival of more than 100 days. Long-living recipients permanently accepted donor-strain heterotopic hearts transplanted on the same day or donor-strain skin 3 mo after liver transplantation, in spite of detectable antidonor in vitro activity with mixed lymphocyte reaction and cell-mediated lymphocytotoxicity testing (split tolerance). In further donor-specific experiments, liver grafts were not rejected by presensitized major histocompatibility complex class I-disparate recipients and they protected donor-strain skin grafts from second set (or any) rejection. Less frequently, liver transplantation rescued rejecting skin grafts placed 1 wk earlier in major histocompatibility complex class I, class II and minor histocompatibility complex, class II or minor histocompatibility complex-disparate strain combinations. Donor-derived leukocyte migration to the central lymphoid organs occurred within 1 to 2 hr after liver transplantation in all animals examined, persisted in the surviving animals until they were killed (> 375 days), and was demonstrated with double-immunolabeling to be multilineage. The relation of these findings to so-called hepatic tolerogenicity and to tolerance in general is discussed.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0270-9139
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
916-24
|
| pubmed:dateRevised |
2010-12-3
|
| pubmed:meshHeading |
pubmed-meshheading:8138266-Animals,
pubmed-meshheading:8138266-B-Lymphocytes,
pubmed-meshheading:8138266-Graft Rejection,
pubmed-meshheading:8138266-Graft Survival,
pubmed-meshheading:8138266-Heart Transplantation,
pubmed-meshheading:8138266-Histocompatibility Antigens Class I,
pubmed-meshheading:8138266-Histocompatibility Antigens Class II,
pubmed-meshheading:8138266-Immunity, Cellular,
pubmed-meshheading:8138266-Immunohistochemistry,
pubmed-meshheading:8138266-Liver Transplantation,
pubmed-meshheading:8138266-Lymphoid Tissue,
pubmed-meshheading:8138266-Major Histocompatibility Complex,
pubmed-meshheading:8138266-Male,
pubmed-meshheading:8138266-Mice,
pubmed-meshheading:8138266-Skin Transplantation,
pubmed-meshheading:8138266-Specific Pathogen-Free Organisms,
pubmed-meshheading:8138266-Spleen,
pubmed-meshheading:8138266-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:8138266-Transplantation, Homologous,
pubmed-meshheading:8138266-Transplantation Chimera
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Murine liver allograft transplantation: tolerance and donor cell chimerism.
|
| pubmed:affiliation |
Pittsburgh Transplant Institute, University of Pittsburgh Medical Center, Pennsylvania 15213.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|